AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 949108 — intervention group
Group type: COMPARATOR
Intervention: High-dose fentanyl anaesthesia
Number of subjects: 15
Study 31579987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacha inchi microemulsion (SIME) eye drops
Number of subjects: 64
Study 31579987 — intervention group
Group type: COMPARATOR
Intervention: 0.2% hyaluronic acid (HA) control eye drops
Number of subjects: 64
Study 29314176 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 immunohistochemistry (IHC)
Number of subjects: 60
Study 26810604 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 157
Study 26810604 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 157
Study 26810604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 157
Study 24076487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg bid
Number of subjects: 9183
Study 24076487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg bid
Number of subjects: 9183
Study 24076487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran plasma concentrations
Number of subjects: 9183
Study 24076487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran exposure
Number of subjects: 9183
Study 24076487 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 9183
Study 24076487 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA use
Number of subjects: 9183
Study 24076487 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 9183
Study 22713948 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1mg/kg I/M)
Number of subjects: 80
Study 22713948 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (0.5mg/kg I/M)
Number of subjects: 80
Study 19737527 — intervention group
Group type: EXPERIMENTAL
Intervention: LD LSA-NRC/AS01: 10microg LSA-NRC/0.5ml AS01 (n=5)
Number of subjects: 36
Study 19737527 — intervention group
Group type: EXPERIMENTAL
Intervention: HD LSA-NRC/AS01: 50microg LSA-NRC/0.5ml AS01 (n=13)
Number of subjects: 36
Study 19737527 — intervention group
Group type: EXPERIMENTAL
Intervention: LD LSA-NRC/AS02: 10microg LSA-NRC/0.5ml AS02 (n=5)
Number of subjects: 36
Study 19737527 — intervention group
Group type: EXPERIMENTAL
Intervention: HD LSA-NRC/AS02: 50microg LSA-NRC/0.5ml AS02 (n=13)
Number of subjects: 36
Study 19737527 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-immunized infectivity controls)
Number of subjects: 36
Study 17851042 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 to 20 mg/d of oral olanzapine
Number of subjects: 309
Study 17851042 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 309
Study 15983892 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-drug therapies containing zidovudine, stavudine, or other combinations
Number of subjects: 0
Study 15983892 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14622636 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing intervention (detailed information/education session)
Number of subjects: 2
Study 14622636 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2
Study 14622636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 2
Study 10938759 — intervention group
Group type: EXPERIMENTAL
Intervention: ASHBMP Manual
Number of subjects: 150
Study 10938759 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional safety fact sheets)
Number of subjects: 150
Study 8829023 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d of pravastatin
Number of subjects: 48
Study 8829023 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/d of probucol and 600 mg/d of pantethine
Number of subjects: 48
Study 8829023 — intervention group
Group type: COMPARATOR
Intervention: Diet plus exercise therapy
Number of subjects: 48
Study 1349368 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine plus pralidoxime
Number of subjects: 45
Study 1349368 — intervention group
Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 45
Study 3006435 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated mammographic screening
Number of subjects: 92934
Study 3006435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no repeated mammographic screening)
Number of subjects: 92934
Study 31145006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual activity-based HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 0
Study 31145006 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health workers (CBHW) support
Number of subjects: 0
Study 29692290 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized NVS
Number of subjects: 180
Study 29692290 — intervention group
Group type: COMPARATOR
Intervention: Interviewer‐administered NVS
Number of subjects: 180
Study 26732383 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic esophagectomy
Number of subjects: 300
Study 25230684 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual patient simulation (2-hour fully automated)
Number of subjects: 57
Study 25230684 — intervention group
Group type: COMPARATOR
Intervention: Mannequin-based simulation (2-hour facilitator-led)
Number of subjects: 57
Study 25230684 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 57
Study 22311405 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) with Qinggan Lidan Decoction (QLD) during icteric stage and Yigan Jiangmei Decoction (YJD) in non-icteric hyper-aminotransferase stage, alongside Ganciclovir 5 mg/kg every 12 hours for 2 weeks, then 5 mg/kg once a day for 5 days every week for 8 weeks
Number of subjects: 100
Study 22311405 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir 5 mg/kg every 12 hours for 2 weeks, then 5 mg/kg once a day for 5 days every week for 8 weeks, with glucurolactone 50 mg three times per day
Number of subjects: 100
Study 20387548 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0
Study 20387548 — intervention group
Group type: COMPARATOR
Intervention: Registry studies
Number of subjects: 0
Study 17618525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (0.75 to 15.0 mg/day, mean dose 7.12 mg/day)
Number of subjects: 243
Study 17618525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 16287635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance movement therapy (DMT)
Number of subjects: 40
Study 16287635 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 12161482 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 90
Study 12161482 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 180 mg/d
Number of subjects: 90
Study 12161482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10334649 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mmol/d Mg supplement as Mg(OH)2 (approximately 22 mmol Mg/d) for 28 d
Number of subjects: 26
Study 10334649 — intervention group
Group type: COMPARATOR
Intervention: Self-selected diet (approximately 11 mmol Mg/d)
Number of subjects: 26
Study 8611062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.25 g/kg
Number of subjects: 0
Study 8611062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.50 g/kg
Number of subjects: 0
Study 8611062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.75 g/kg
Number of subjects: 0
Study 8611062 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 0 g/kg (Control)
Number of subjects: 0
Study 8611062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (all doses)
Number of subjects: 0
Study 2061363 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional support for high trait anxiety mothers for the first 12 months
Number of subjects: 100
Study 2061363 — intervention group
Group type: COMPARATOR
Intervention: Non-professional support for high trait anxiety mothers for the first 12 months
Number of subjects: 100
Study 6418189 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 47
Study 6418189 — intervention group
Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 47
Study 31425607 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing sessions (8 individual sessions)
Number of subjects: 40
Study 31425607 — intervention group
Group type: COMPARATOR
Intervention: Control group (preferred recreational activities such as playing computer games or watching movies)
Number of subjects: 40
Study 29364063 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% sucrose solution (CHO)
Number of subjects: 18
Study 29364063 — intervention group
Group type: COMPARATOR
Intervention: Flavour and taste matched placebo solution (PLA)
Number of subjects: 18
Study 29364063 — intervention group
Group type: COMPARATOR
Intervention: No rinse (CON)
Number of subjects: 18
Study 27828867 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple maneuver group
Number of subjects: 88
Study 27828867 — intervention group
Group type: COMPARATOR
Intervention: Conventional maneuver group
Number of subjects: 88
Study 23001190 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of melatonin taken 11 h before baseline sleep midpoint, then 1 h earlier on subsequent days
Number of subjects: 12
Study 23001190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21600325 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (1‐34) treatment
Number of subjects: 39
Study 19566557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cervical dilatation (Group A)
Number of subjects: 400
Study 19566557 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative cervical dilatation (Group B)
Number of subjects: 400
Study 17163236 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment in RA patients
Number of subjects: 619
Study 17163236 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment in PsA patients
Number of subjects: 619
Study 17163236 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption in RA and PsA patients
Number of subjects: 619
Study 15520038 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education interventions, particularly interpersonal communication
Number of subjects: 0
Study 15520038 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11139949 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg/day)
Number of subjects: 214
Study 11139949 — intervention group
Group type: COMPARATOR
Intervention: Sotalol (320 +/- 20 mg/day)
Number of subjects: 214
Study 11139949 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (450 mg/day)
Number of subjects: 214
Study 11139949 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 214
Study 11139949 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 214
Study 11139949 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 214
Study 11139949 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone vs Propafenone
Number of subjects: 214
Study 11139949 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone and Propafenone
Number of subjects: 214
Study 9052642 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 70
Study 9052642 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 70
Study 8364941 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (I-C)
Number of subjects: 106
Study 8364941 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus tobramycin (C&T)
Number of subjects: 106
Study 3723137 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 million units of human lymphoblastoid interferon (Wellferon) three times a week for three months
Number of subjects: 37
Study 3723137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 million units of human lymphoblastoid interferon (Wellferon) three times a week for three months
Number of subjects: 37
Study 31692188 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab 120 mg
Number of subjects: 0
Study 31692188 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab 240 mg
Number of subjects: 0
Study 31692188 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31692188 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab
Number of subjects: 0
Study 29911909 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded spurs
Number of subjects: 81
Study 29911909 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin cup
Number of subjects: 81
Study 29911909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed palatal crib
Number of subjects: 81
Study 29911909 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable palatal crib
Number of subjects: 81
Study 27444494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg (test)
Number of subjects: 32
Study 27444494 — intervention group
Group type: COMPARATOR
Intervention: Valoid 50 mg (reference)
Number of subjects: 32
Study 27444494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 32
Study 24002927 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of risedronate sodium 35 mg
Number of subjects: 48
Study 24002927 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of risedronate sodium 35 mg
Number of subjects: 48
Study 22918218 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) examination every 2 hr until intracranial brain death flow patterns were found
Number of subjects: 44
Study 19682803 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of exercise (70 VO(2max))
Number of subjects: 12
Study 19682803 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 12
Study 19682803 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n=12)
Number of subjects: 12
Study 18280104 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise program (WEP)
Number of subjects: 22
Study 18280104 — intervention group
Group type: COMPARATOR
Intervention: Standard ward care
Number of subjects: 22
Study 18641105 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg/kg fospropofol
Number of subjects: 252
Study 18641105 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg fospropofol
Number of subjects: 252
Study 14689224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal instillation of lidocaine-prilocain cream (n=75)
Number of subjects: 198
Study 14689224 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic anesthesia with 2% lidocaine (n=80)
Number of subjects: 198
Study 14689224 — intervention group
Group type: COMPARATOR
Intervention: Control group with sonographic gel intrarectally (n=40)
Number of subjects: 198
Study 11738354 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal muscular atrophy group (n=96)
Number of subjects: 96
Study 11738354 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-affected siblings (n=45)
Number of subjects: 96
Study 11738354 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=59)
Number of subjects: 96
Study 11738354 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children and adolescents with spinal muscular atrophy (SPM only)
Number of subjects: 96
Study 11738354 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children and adolescents with spinal muscular atrophy (Wechsler tests)
Number of subjects: 96
Study 9376574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 10 microg/kg/d filgrastim and 20 microg/kg/d SCF for 7 days
Number of subjects: 215
Study 9376574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 10 microg/kg/d filgrastim and 25 microg/kg/d SCF for 7 days
Number of subjects: 215
Study 9376574 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim alone (10 microg/kg/d for 7 days)
Number of subjects: 215
Study 8163051 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine glucose self-monitoring (UGSM)
Number of subjects: 181
Study 8163051 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose self-monitoring (BGSM)
Number of subjects: 181
Study 8163051 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 181
Study 3285837 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg torasemide
Number of subjects: 19
Study 3285837 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg torasemide
Number of subjects: 19
Study 3285837 — intervention group
Group type: COMPARATOR
Intervention: 250 mg furosemide
Number of subjects: 19
Study 11886505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B + Ultraviolet A sunblock (SPF 15)
Number of subjects: 28
Study 11886505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B sunblock (SPF 15)
Number of subjects: 28
Study 11886505 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated skin
Number of subjects: 28
Study 29528807 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Training Group (DBTSTG)
Number of subjects: 82
Study 29528807 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy Group (CTG)
Number of subjects: 82
Study 29955803 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (10 Hz, 120% motor threshold, 4000 pulses/session)
Number of subjects: 164
Study 29955803 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 164
Study 29955803 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 164
Study 26956875 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound kushen injection in combination with single-agent chemotherapy
Number of subjects: 370
Study 26956875 — intervention group
Group type: COMPARATOR
Intervention: Standard platinum-based doublet chemotherapy
Number of subjects: 370
Study 24607773 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual ETA/ETB receptor blockade
Number of subjects: 12
Study 24607773 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective ETA blockade
Number of subjects: 12
Study 24607773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both selective ETA blockade and dual ETA/ETB blockade
Number of subjects: 12
Study 24607773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 12
Study 24607773 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual ETA/ETB blockade
Number of subjects: 12
Study 22490717 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 228
Study 22490717 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 228
Study 20192279 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study 17299116 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein (HP, 30% protein)
Number of subjects: 46
Study 17299116 — intervention group
Group type: COMPARATOR
Intervention: Normal protein (NP, 18% protein)
Number of subjects: 46
Study 15644655 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily
Number of subjects: 24
Study 15644655 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice daily
Number of subjects: 24
Study 12117361 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (oral administration for a 5-month period)
Number of subjects: 15
Study 12117361 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control subjects)
Number of subjects: 15
Study 9933049 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (titrated to doses of 2, 4, 8, or 12 mg once daily)
Number of subjects: 248
Study 9933049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 8578253 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I: follow-up every three months for the first two years and every six months in the third year, thereafter once a year.
Number of subjects: 97
Study 8578253 — intervention group
Group type: COMPARATOR
Intervention: Regimen II: follow-up every six months for the first year and once a year thereafter.
Number of subjects: 97
Study 8578253 — intervention group
Group type: COMPARATOR
Intervention: Regimen II
Number of subjects: 97
Study 2104987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐3505
Number of subjects: 12
Study 2104987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788
Number of subjects: 12
Study 2104987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 836384 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection treatment (partial duodenopancreatectomy, subtotal left pancreatic resection)
Number of subjects: 201
Study 836384 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial duodenopancreatectomy and subtotal left resection
Number of subjects: 201
Study 836384 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative diabetes
Number of subjects: 201
Study 30869165 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 0
Study 30869165 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 0
Study 30869165 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 0
Study 30869165 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 2, 4, 8, and 12 mg
Number of subjects: 0
Study 30869165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28944358 — intervention group
Group type: EXPERIMENTAL
Intervention: Full arch zirconia framework hand-veneered with ceramic
Number of subjects: 24
Study 28944358 — intervention group
Group type: COMPARATOR
Intervention: Full arch zirconia framework hand-veneered with composite
Number of subjects: 24
Study 26662217 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10
Number of subjects: 437
Study 24357423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal parastomal mesh placement
Number of subjects: 10
Study 23151693 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphala
Number of subjects: 30
Study 23151693 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi Ora
Number of subjects: 30